Baird Reiterates an 'Outperform' on Regeneron Pharma (REGN); View ACC As Coming Out Party

Baird reiterates an 'Outperform' on Regeneron Pharma (NASDAQ: REGN) price target of $120.00.

Analyst, Christopher Raymond, said, "While much of REGN's recent outperformance (+110% YTD, NBI +15%) can be attributed to Eylea's impressive early launch, we remind investors that the next significant pipeline agent - REGN727, REGN's anti-PCSK9 antibody - will have key Phase II data this weekend at ACC. Given this, and given that Phase III trials are slated to begin 1H12, we think REGN727 is poised to become a more emergent value driver. "

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $116.46 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy